The Efficacy and Complications of Rifampin-combined Antibiotic Therapy for Staphylococcal Periprosthetic Joint Infections (PJI): A Multicenter, Randomized Controlled Trial

What this Trial Is About

Researchers are evaluating the use of rifampicin combined with antibiotics to treat periprosthetic joint infections (PJI) caused by staphylococcus bacteria. This multicenter, randomized controlled study focuses on patients who have undergone DAIR surgery and aims to compare infection control rates and safety between two treatment approaches over at least a two-year follow-up period. The study follows CONSORT guidelines and ensures ethical approval and informed consent from participants. After surgery, all patients receive intravenous antibiotics for 1 to 2 weeks. Then, they are randomly assigned to one of two groups: one group receives conventional antibiotics (fluoroquinolones or linezolid) for 3 months based on microbial culture results, while the other group receives the same antibiotics plus oral rifampicin for 3 months. Both groups are monitored to assess the differences in infection control and safety outcomes. Participants will undergo regular assessments including infection recurrence rates, inflammatory markers, prosthesis function recovery, and monitoring for drug side effects. Data is collected through a unified system and analyzed at the study's end. The primary outcomes include infection clearance and adverse events related to PJI two years after surgery. Secondary outcomes include functional scores, prosthesis loosening, revision rates, prosthesis removal, and antibiotic complications. The study duration per participant covers at least two years of follow-up.

Rifampin-combined Antibiotic Therapy for Staphylococcal PJI